Key facts

Active Substance
  • Pneumococcal polysaccharide serotype 3
  • Pneumococcal Polysaccharide Serotype 8
  • Pneumococcal Polysaccharide Serotype 15C
  • Pneumococcal polysaccharide serotype 6A
  • Pneumococcal Polysaccharide Serotype 15A
  • Pneumococcal Polysaccharide Serotype 16F
  • Pneumococcal polysaccharide serotype 19A
  • Pneumococcal Polysaccharide Serotype 23A
  • Pneumococcal Polysaccharide Serotype 24F
  • Pneumococcal Polysaccharide Serotype 17F
  • pneumococcal polysaccharide serotype 33F – diphtheria CRM197 conjugate (15-valent pneumococcal polysaccharide conjugate vaccine [V114])
  • Pneumococcal polysaccharide serotype 10A
  • Pneumococcal polysaccharide serotype 12F
  • Pneumococcal Polysaccharide Serotype 20
  • Pneumococcal Polysaccharide Serotype 31
  • Pneumococcal Polysaccharide Serotype 35B
  • Pneumococcal polysaccharide serotype 7F
  • Pneumococcal Polysaccharide Serotype 22F
  • Pneumococcal Polysaccharide Serotype 9N
  • Pneumococcal polysaccharide serotype 11A
  • Pneumococcal Polysaccharide Serotype 23B
Therapeutic area
Vaccines
Decision number
P/0485/2022
PIP number
EMEA-003155-PIP01-21
Pharmaceutical form(s)
Solution for injection in pre-filled syringe
Condition(s) / indication(s)
Prevention of disease caused by Streptococcus pneumoniae
Route(s) of administration
Intramuscular use
Contact for public enquiries

Merck Sharp & Dohme (Europe) Inc.

Tel.: +33180464738
E-mail: pip.information@merck.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date

Decision

Share this page